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ABSTRACT 
Unlike patients with either hypertension (I-IT) or angina pectoris (AP) 
alone, patients with both HT and AP usually have a reduced left ven- 
tricular compliance and may, therefore, have an impaired capability 
to cope with acute hemodynamic changes generated by standard beta- 
blockers or calcium channel blockers. Celiprolol has been documented 
to produce fewer adverse effects and equal efficacy compared with 
standard beta-blockers or calcium channel blockers. We carried out a 
16-week open-label, sequential comparison of standard monotherapy 
versus celiprolol in 172 patients with either HT alone, AP alone, or HT 
+ AP. We compared the effects on symptoms and adverse effects. The 
occurrence of adverse effects from drug therapy was definitely more 
common in the HT + AP patients than in patients with AP alone or HT 
alone. Despite this imbalance in the groups, celiprolol overall pro- 
duced fewer occurrences of fatigue, dizziness, and edema. Celiprolol 
controlled AP and HT to the same extent as did standard monother- 
apy. Our data, although preliminary, suggest that patients with both 
HT and AP are prone to adverse effects of standard drug therapy, and 
that celiprolol, while equally effective, is largely devoid of adverse 
effects as compared with standard therapy, particularly in patients 
with both HT and AP. 
INTRODUCTION 
Patients with both hypertension (HT) and coronary artery disease such as 
angina pectoris (AP) usually have a reduced left ventricular compliance as 
measured by a prolonged filling time.ls2 Such properties may impair their 
capability to cope with the hemodynamic changes generated by beta- 
blockers and calcium channel blockers. Considering that common adverse 
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effects with these drugs such as hypotension, fatigue, and reduced exer- 
cise tolerance have been largely attributed to hemodynamic effects,3-6 
we assumed that patients with HT and AP would be prone to ad- 
verse effects with standard drug therapy. This has not been tested, 
however. 
Celiprolol is a representative of a new class of selective beta-blockers 
with vasodilatory beta,-agonistic properties7 and has been documented to 
combine lower scores of adverse effects with equal efficacy when compared 
with standard beta-blockers or calcium channel blockers.8’g Celiprolol had 
not been tested, however, in patients with both HT and AP. 
The first objective of this study was to determine whether patients 
with HT and AP would be prone to adverse effects of standard drug therapy 
compared with patients with either AP or HT alone. Secondly, we assessed 
the effects of celiprolol in these three groups of patients. 
PATIENTS AND METHODS 
Patients and Study Design 
We conducted a lgweek, across-group, multicenter comparison of 
monotherapy with various beta-blockers or calcium channel blockers and 
monotherapy with celiprolol. Patients were recruited from the outpatient 
clinics of the cardiology departments of 16 hospitals in The Netherlands. 
Criteria for qualification were a diagnosis of mild essential hypertension 
according to the criteria of the Joint National Committee” (resting heart 
rate >140/90 mm Hg and <170/110 mm Hg) or stable angina pectoris 
(New York Heart Association class I or II, or effort-induced AP). A total of 
205 patients not older than 80 years of age were enrolled. 
After giving informed consent, all of the patients were treated for 8 
weeks with equipotent doses of standard beta-blockers (metoprolol 100 to 
200 mg daily in 21 patients, sotalol 40 to 80 mg daily in 40 patients, and 
atenolol 50 to 100 mg daily in 49 patients) or standard doses of calcium 
channel blockers (nifedipine 20 to 30 mg daily in 32 patients and diltiazem 
60 to 120 mg daily in 21 patients). The remaining nine patients (5%) were 
treated with a combination of these beta-blockers and calcium channel 
blockers using the lowest dosages as mentioned above. The treatment reg- 
imens were chosen by the participating cardiologists and were standard for 
their institutions. After 8 weeks these treatments were replaced by celi- 
pro101 200 to 400 mg once daily in all patients. 
Evaluation 
Patients were evaluated by their cardiologists at the outpatient clinic 
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Table I. Patient characteristics. 
HT + AP 




Chronic obstructive pulmonary disease (n) 






Left ventricular hypertrophy (n) 
Ejection fraction* ~45% (n) 
HT = hypertension; AP = angina pectoris. 
* These patients were allowed to continue taking low doses (10 mg daily) of enalapril, an angiotensin- 
converting enzyme inhibitor. 
at baseline and after 8 and 16 weeks of treatment (Table II). Evaluation 
consisted of a medical history and physical examination, measurements of 
sitting blood pressure, and an electrocardiogram. Blood pressure was mea- 
sured (average of three measurements) after 10 minutes of rest, by aus- 
cultation with a mercury manometer. The diastolic value was taken as the 
start of the Korotkoff sounds phase IV. Assessment of adverse effects and 
symptoms of AP was performed after 8 and 16 weeks of treatment using a 
questionnaire based on the quality-of-life questionnaire of Bulpitt and 
Fletcher for patients with HT” and the quality-of-life questionnaire of 
Marquis, Fayol, and Joire for patients with AP.l’ Both of these question- 
naires have a negligible within-subject test/retest variability in untreated 
subjects. The questionnaires were self-administered by the patient after 
explicit instruction by a test assistant and required about 20 minutes to 
complete. The test assistant was unaware of the treatments given. All 
patients were given both questionnaires. Consent for the study was ob- 
tained from all of the participating centers’ ethics committees. 
Table II. Study evaluations. 
Medical history 
Physical examination 
Sitting blood pressure 
Electrocardiogram 
Quality of life 
Standard Therapy Celiprolol 200400 mg od 
Baseline Week 8 Week 16 
X X X 
X X X 
X X X 
X X X 
X X 
od = once daily 
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Statistical Analysis 
Data were analyzed using analysis of variance or the chi-square anal- 
ysis of contingency table with use of the Bonferroni inequality to adjust 
between-group P values. 
RESULTS 
Of the 205 patients originally enrolled, 172 were included in the final 
analysis. Of the 33 that were excluded, 19 were lost to follow-up, 14 during 
the first 8 weeks of the study, and 14 were excluded because their ques- 
tionnaires were only partly answered. Characteristics of the remaining 
172 patients are shown in Table I. Patients with both AP and HT had a 
greater incidence of chronic obstructive pulmonary disease at enrollment 
(HT + AP vs AP alone and HT + AP vs HT alone, both P = 0.0008). AP 
patients had less left ventricular hypertrophy than the HT and HT + AP 
groups (both P = 0.001). Patients with a compromised left ventricular 
ejection fraction were allowed to continue taking low-dose enalapril 10 mg 
daily. Other medications that were allowed included aspirin and short- 
acting nitrates ad libitum. 
Table III shows the effects of the two treatment modalities. The effects 
on diastolic blood pressure and symptoms of AP were similar between the 
groups. Celiprolol controlled AP to the same extent as did standard ther- 
apy. Table IV shows that with both standard therapy and with celiprolol 
the occurrence of adverse effects was significantly different between the 
various groups. Multiple comparison analysis confirmed that this was 
mainly due to a significantly larger number of patients with adverse ef- 
Table III. Effects of standard monotherapy* or celiprolol in patients with hypertension (HT) 
alone, angina pectoris CAP) alone, or HT + AP. 
HT + AP 
(n = 47) (n !‘G*) 
P Between 
Groups 
Diastolic blood pressure 690 mm Hg 
Standard 
Celiprolol 




Celiprolol better than standard 
Same 








l Ninety-five percent of the patients were receiving monotherapy with either a beta-blocker (64%) or a 
calcium channel blocker (31%); the remaining 5% were receiving combined therapy with a calcium channel 
blocker plus a beta-blocker. 
t Controlled means virtually no AP attacks. 
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Table IV. Adverse effects of standard monotherapy* or celiprolol in patients with hyperten- 
sion (HT) alone, angina pectoris (AF’) alone, or HT + Ap. 
HT + AP 


























5 11% I 1 
(n ip9*) 
7 8% I I 2 2% 
7 8% I 1 3 3% 
5 5% I I 3 9% 3 3% I I 2 6% 






7 21% I 1 4 12% %iol 
3 9% I I 3 9% <ofiFo1 
2 6% I I 0.46 2 6% NS 
1 I 3% I 0.0003 1 3  0.08 
l Ninety-five percent of the patients were receiving monotherapy with either a beta-blocker (64%) or a 
calcium channel blocker (31%); the remaining 5% were receiving combined therapy with a calcium channel 
blocker plus a beta-blocker. 
fects in the HT + AP group than in either the AP group or HT group. 
During standard therapy this was true for the variables fatigue (P < 
O.OOl), reduced libido (P < 0.011, headache (P < 0.011, dizziness (P < 0.02), 
edema (P < 0.02), and dyspnea (P < 0.021, and during celiprolol for fatigue 
(P < 0.05), edema (P < 0.051, and dizziness (P < 0.02). Despite this im- 
balance in the groups, celiprolol overall produced significantly better 
scores for fatigue, dizziness, and edema, whereas in most of the other 
categories a trend was seen toward better scores with celiprolol as well 
(Table V). 
DISCUSSION 
Important indicators for calcium channel blockers and beta-blockers are 
HT and AP. Although these compounds substantially reduce blood pres- 
sure in patients with HT, their effect on blood pressure in patients with AP 
is little.13 In addition, patients with both HT and AP have a reduced left 
ventricular compliance that may impair their ability to cope with hemo- 
dynamic changes generated by therapy with these drugs. Therefore, 
across-group analyses of effects and side effects of these drugs may be 
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Table V. Adverse effects of therapy with celiprolol versus standard monotherapy* in patients 
with hypertension (HP) alone, angina pectoris (Al’) alone, or HT + AP. 
HT + AP 




Mmp~iol better than standard 
Standard better than celiprolol 
Fatigue 
Mi&olol better than standard 
Standard better than celiprolol 
Reduced libido 
;;Zepolol better than standard 
Standard better than celiprolol 
Arrhythmia 
C&;p;lol better than standard 
Standard better than celiprolol 
Headache 
rZ;;p~lol better than standard 







better than standard 
better than celiprolol 
better than standard 




Mi&~lol better than standard 
Standard better than celiprolol 
l Nine 
T channe 
-five percent of patients were receiving monotherapy with either a beta-blocker (64%) or a calcium 
blocker (31%); the remaining 5% were receiving combined therapy with a calcium channel blocker 
plus beta-blocker. 
clinically relevant, but it has drawn little attention from investigators so 
far. The current study is a preliminary effort to address this issue. 
Beta-blockers and calcium channel blockers are routinely prescribed, 
either separately or in combination, for patients with HT or AP. Calcium 
channel blockers inhibit calcium ion (Ca+ ‘) influx through calcium chan- 
nels in the cells, thus inducing vasodilation and chronotropic effects. Beta- 
blockers act on Ca+ + channels indirectly by inactivating cyclic adenosine 
monophosphate-dependent protein kinase, which phosphorylates calcium 
subunits, and thereby results in a decrease in the probability of calcium 
channel opening. So, while both compounds are helpful in inactivating 
calcium channels, beta-blockers do so more effectively in the heart, leading 
to bradycardia, and calcium channel blockers do so in the resistance ves- 
sels, leading to reduced afterload. Both of these modalities of action lead to 
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a considerable fall of blood pressure, which is counteracted in the case of 
beta-blockers by an increase of stroke volume, and in the case of calcium 
channel blockers by a reflexogenic increase of both heart rate and stroke 
volume. 
The documented deficiency of such mechanisms in patients with both 
HT and AP1,2 may be responsible for the presence of a significantly greater 
incidence of adverse effects from these drugs in patients with HT and AP 
than in the HT alone and AP alone groups. This would mean that in this 
category of patients treatment dosages should be carefully titrated and 
alternative compounds should be considered. 
Celiprolol reduces heart rate and cardiac output to a lesser extent than 
standard beta-blockerq7 and it causes afterload reduction to a lesser ex- 
tent than calcium channel blockers without causing reflex tachycardia.8 
These characteristics may partly explain why celiprolol produced fewer 
adverse effects, particularly in the group with HT and AP. The combina- 
tion of a low-dose calcium channel blocker and a standard beta-blocker 
might be as effective as a beta-blocker with vasodilatory effects such as 
celiprolol, however, there are documented risks in combination therapy of 
drug interaction causing enhanced possibilities of serious hypotension as 
well as serious bradycardia.4-6 Also, combination therapy is less conve- 
nient to patients than monotherapy. In our study, unlike other studies, the 
group of patients with HT and AP was substantial. There are few data in 
the literature about the prevalence of HT and AP, although HT has been 
recognized as a major risk factor for coronary artery disease. HT and AP 
generally are studied by different disciplines. A diagnosis of AP may be 
deemphasized in HT studies, as may be a diagnosis of HT in AP studies. 
The actual prevalence of coronary artery disease in hypertensive patients 
thus may be underestimated. 
CONCLUSIONS 
Our data need to be confirmed through further study, but they suggest that 
patients with HT and AP are prone to adverse effects from standard ther- 
apy with beta-blockers or calcium channel blockers. This particular cate- 
gory of patients may benefit from treatment with beta-blockers with va- 
sodilatory, beta-agonistic properties, such as celiprolol. 
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